# BioAtla

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioatla

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.bioatla.com
- Total disclosed funding: $73M
- Latest round: Series D (Jun 10, 2020)
- Investors on record: 6

## About

BioAtla, Inc. is a biopharmaceutical company focused on developing innovative conditionally active biologics (CABs) to enhance cancer treatment efficacy while minimizing side effects.Founded in 2007, BioAtla, Inc. operates from San Diego, US, specializing in the development of conditionally active biologics for oncology. The company has completed 8 funding deals, with the most recent PIPE round raising USD 65.00 mn in December 2020 from notable investors including Acuta Capital Partners and Adage Capital Management. CEO Jay Short co-founded the company with Masood Tayebi.BioAtla specializes in the development of conditionally active biologics (CABs), a class of therapeutics designed to enhance the efficacy and safety of cancer treatments. Their technology enables the creation of antibodies and other biologics activated by specific physiological conditions, targeting the tumor microenvironment for improved therapeutic indices. The firm caters to healthcare providers, research institutions, and pharmaceutical companies globally, primarily in North America, Europe, and select markets in Asia.In 2024, BioAtla reported revenue of USD 11.00 mn, with an EBITDA of USD -73.02 mn. Revenue is generated through strategic partnerships and collaborations with pharmaceutical companies and research institutions, structured around licensing agreements and milestone payments associated with the development of their CAB technology.BioAtla plans to utilize the funding raised in December 2020 to design, implement, and execute clinical programs evolving from its CAB platform. The company is targeting the expansion of its product offerings and aims to enter new geographic markets to enhance its operational footprint in the biopharmaceutical sector.

## Funding rounds

- Series D, Jun 10, 2020, $73M — HBM Partners, Pappas Capital, Pfizer Venture Investments, Cormorant Asset Management, Farallon Capital Management, Soleus Capital

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Pappas Capital (https://capitalatlas.ai/funds/pappas-capital) — Series D
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series D
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series D